For decades, obesity medications produced only modest weight loss. But in recent years, Ozempic and related GLP-1 therapies have transformed the field, enabling sustained weight loss of 10 to 15% or more. Despite their success, however, scientists have not fully understood how these drugs work in the brain.Now, in a new study, Yale researchers have identified an unexpected mechanism of action that challenges a long-held assumption about the brain’s hunger circuitry: that agouti-related peptide (AgRP) neurons, known as drivers of hunger, functioned solely to oppose weight loss. However, the new study shows that GLP-1 therapies like Ozempic instead recruit these neurons to help sustain fat loss.
How have GLP-1s transformed obesity medicine?For decades, obesity medications produced only modest weight loss. Ozempic and related GLP-1 therapies transformed the field, enabling sustained weight loss of 10 to 15% or moreWhat is the prevailing view of how GLP-1s work?One of the prevailing views has been that GLP-1 drugs promote weight loss by reducing the activity of agouti-related peptide (AgRP) neurons that drive hunger. Although this hypothesis has been widely discussed, the role of AgRP neurons in weight loss during chronic GLP-1 treatment had not been directly tested in vivo until a new study from Yale. How does Ozempic actually work?In a new study, Yale researchers uncovered a previously unrecognized mechanism that challenged the classic idea of how Ozempic works. Rather than only suppressing appetite, they found that chronic GLP-1 treatment also recruits hunger neurons, triggering metabolic adaptations that contributes to fat loss, similar to what normally happens when the organism is under calorie deficiency.
